As Chief Corporate Development Officer of ELIQUENT Life Sciences, Andreas Tsitsos is responsible for guiding the company’s mergers & acquisitions activity, and, in addition, he also leads the company’s Transformation Management Office (“TMO”), a cross-functional team responsible for business transformation initiatives and integrations.

Andreas has over 15 years of experience in M&A and corporate finance, most of which has come in the life sciences industry, and brings that perspective to his day-to-day role as Eliquent’s corporate development leader. He has played a key role in our acquisition of RApport and leads our continued efforts to expand our services lines and geographic presence through acquisitions and strategic partnerships. Through his leadership of the TMO, Andreas has helped bring together our legacy organizations while helping to position the organization for organic growth and create a platform for integrating future acquisitions.

Prior to joining ELIQUENT, Andreas served as Vice President, Finance and Operations, at Exeevo, a life sciences CRM start-up, where he built and led the company’s support functions and completed Exeevo’s spin-out from its former parent. He also played a key role as a member of the corporate development team at Syneos Health, including merging INC Research and inVentiv Health to form Syneos while also leading numerous tuck-in acquisitions and divestitures for the organization. Andreas began his career in the Corporate Finance & Restructuring practice of FTI Consulting, where he advised debtors and creditors in distressed situations.